Author

R. S. Nargi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Assay:proteomics· 5 Research Focus:host-pathogen & immune response· 4 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Research Focus:cell type annotation· 1 Organism:non-human primate· 1

Frequent Co-Authors

J. E. Crowe· 7 shared R. H. Carnahan· 7 shared N. Suryadevara· 6 shared P. Gilchuk· 6 shared R. E. Sutton· 5 shared S. J. Zost· 5 shared M. S. Diamond· 4 shared D. R. Martinez· 3 shared

Activity by Year

2020-2021 · peak 6/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

J. E. Crowe

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Protective pan-ebolavirus combination therapy by two multifunctional human antibodies

P. Gilchuk, C. D. Murin, R. W. Cross, P. A. Ilinykh, K. Huang, N. Kuzmina, V. Borisevich, K. N. Agans, J. B. Geisbert, R. H. Carnahan, R. S. Nargi, R. E. Sutton, N. Suryadevara, S. J. Zost, R. G. Bombardi, , J. E. Crowe

This paper develops a therapeutic cocktail of two human antibodies that protect against multiple ebolaviruses in non-human primates and reveals their molecular mechanisms.

bioRxiv · May 2, 2021 · PreprintImmunology

Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface

S. J. Zost, J. Dong, I. M. Gilchuk, P. Gilchuk, N. J. Thornburg, S. Bangaru, N. Kose, J. A. Finn, R. Bombardi, C. Soto, R. S. Nargi, R. P. Irving, N. Suryadevara, J. B. Westover, R. H. Carnahan, , J. E. Crowe

The paper identifies common genetic and structural features of human antibodies recognizing the influenza HA trimer interface, suggesting it as a target for vaccine design.

bioRxiv · Dec 31, 2020Immunology

Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions

A. R. Shiakolas, K. J. Kramer, D. Wrapp, S. I. Richardson, A. Schäfer, S. Wall, N. Wang, K. Janowska, K. A. Pilewski, R. Venkat, R. Parks, N. P. Manamela, N. Raju, E. Friedman Fechter, C. M. Holt, , I. S. Georgiev

The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.

bioRxiv · Dec 20, 2020 · PreprintImmunology

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

A. J. Greaney, T. N. Starr, P. Gilchuk, S. J. Zost, E. Binshtein, A. N. Loes, S. K. Hilton, J. Huddleston, R. Eguia, K. H. Crawford, A. S. Dingens, R. S. Nargi, R. E. Sutton, N. Suryadevara, P. W. Rothlauf, , J. D. Bloom

This study maps mutations in the SARS-CoV-2 spike RBD that escape antibody recognition, revealing escape mutation patterns and enabling the design of antibody cocktails.

bioRxiv · Sep 10, 2020Microbiology

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, , J. E. Crowe

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

bioRxiv · May 22, 2020Immunology

Integrated technology platform for accelerated discovery of antiviral antibody therapeutics

P. Gilchuk, R. G. Bombardi, J. H. Erasmus, Q. Tan, R. S. Nargi, C. Soto, P. Abbink, T. J. Suscovich, L. A. Dunellin, A. Khandhar, J. Archer, J. Liang, M. E. Fouch, E. Davidson, B. Doranz, , R. H. Carnahan

This study develops an integrated platform to rapidly discover and validate potent antiviral human monoclonal antibodies against Zika virus.

bioRxiv · May 12, 2020Immunology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

bioRxiv · May 12, 2020Immunology